• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在临床试验中测试多种剂量组合。

Testing multiple dose combinations in clinical trials.

作者信息

Saha Saswati, Brannath Werner, Bornkamp Björn

机构信息

Competence Centre for Clinical Trials, University of Bremen, Germany.

Novartis Pharma, Basel, Switzerland.

出版信息

Stat Methods Med Res. 2020 Jul;29(7):1799-1817. doi: 10.1177/0962280219871969. Epub 2019 Sep 24.

DOI:10.1177/0962280219871969
PMID:31549566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7309363/
Abstract

Drug combination trials are often motivated by the fact that individual drugs target the same disease but via different routes. A combination of such drugs may then have an overall better effect than the individual treatments which has to be verified by clinical trials. Several statistical methods have been explored that discuss the problem of comparing a fixed-dose combination therapy to each of its components. But an extension of these approaches to multiple dose combinations can be difficult and is not yet fully investigated. In this paper, we propose two approaches by which one can provide confirmatory assurance with familywise error rate control, that the combination of two drugs at differing doses is more effective than either component doses alone. These approaches involve multiple comparisons in multilevel factorial designs where the type 1 error can be controlled first, by bootstrapping tests, and second, by considering the least favorable null configurations for a family of union intersection tests. The main advantage of the new approaches is that their implementation is simple. The implementation of these new approaches is illustrated with a real data example from a blood pressure reduction trial. Extensive simulations are also conducted to evaluate the new approaches and benchmark them with existing ones. We also present an illustration of the relationship between the different approaches. We observed that the bootstrap provided some power advantages over the other approaches with the disadvantage that there may be some error rate inflation for small sample sizes.

摘要

药物联合试验的动机通常是,单一药物虽针对同一种疾病,但作用途径不同。那么,这类药物的联合使用可能比单一治疗具有更好的总体效果,这一点必须通过临床试验来验证。已经探索了几种统计方法来讨论将固定剂量联合疗法与其各成分进行比较的问题。但是,将这些方法扩展到多剂量联合可能很困难,并且尚未得到充分研究。在本文中,我们提出了两种方法,通过这两种方法可以在控制家族性错误率的情况下提供确证保证,即两种不同剂量的药物联合使用比单独使用任何一种成分剂量更有效。这些方法涉及多级析因设计中的多重比较,其中第一类错误可以首先通过自抽样检验来控制,其次通过考虑联合交集检验族的最不利零假设配置来控制。新方法的主要优点是其实施简单。通过一个降压试验的真实数据示例说明了这些新方法的实施过程。还进行了广泛的模拟,以评估新方法并与现有方法进行比较。我们还展示了不同方法之间的关系。我们观察到,自抽样检验相对于其他方法具有一些功效优势,缺点是对于小样本量可能会出现一些错误率膨胀。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/365e754ecd4a/10.1177_0962280219871969-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/32dc80007136/10.1177_0962280219871969-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/b98d60dffde9/10.1177_0962280219871969-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/365e754ecd4a/10.1177_0962280219871969-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/32dc80007136/10.1177_0962280219871969-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/b98d60dffde9/10.1177_0962280219871969-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f44/7309363/365e754ecd4a/10.1177_0962280219871969-fig3.jpg

相似文献

1
Testing multiple dose combinations in clinical trials.在临床试验中测试多种剂量组合。
Stat Methods Med Res. 2020 Jul;29(7):1799-1817. doi: 10.1177/0962280219871969. Epub 2019 Sep 24.
2
Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.联合治疗试验中多个终点的多重交并检验的性质
J Biopharm Stat. 2001;11(3):125-38. doi: 10.1081/BIP-100107653.
3
Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis.区分联合治疗效果所需的样本量:结核性脑膜炎患者的联合治疗与标准治疗比较的随机对照试验与析因设计。
Trials. 2011 Feb 2;12:26. doi: 10.1186/1745-6215-12-26.
4
Resampling in multiple-dose factorial designs.多剂量析因设计中的重采样
Biom J. 2009 Dec;51(6):915-31. doi: 10.1002/bimj.200900129.
5
Cumulative statistical power for hierarchical comparisons to evaluate two combination drug doses.用于评估两种联合药物剂量的分层比较的累积统计功效。
J Biopharm Stat. 2008;18(4):750-72. doi: 10.1080/10543400802071428.
6
Accurate p-values for adaptive designs with binary endpoints.具有二元终点的适应性设计的准确p值。
Stat Med. 2017 Jul 30;36(17):2643-2655. doi: 10.1002/sim.7324. Epub 2017 May 3.
7
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.随机对照试验中的亚组分析:量化假阳性和假阴性风险
Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330.
8
Trial designs for evaluating combination HIV prevention approaches.评估联合 HIV 预防方法的试验设计。
HIV Res Clin Pract. 2020 Apr-Jun;21(2-3):72-82. doi: 10.1080/25787489.2020.1798083. Epub 2020 Jul 23.
9
Adding new experimental arms to randomised clinical trials: Impact on error rates.在随机临床试验中增加新的实验组:对误差率的影响。
Clin Trials. 2020 Jun;17(3):273-284. doi: 10.1177/1740774520904346. Epub 2020 Feb 17.
10
Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials.在非平衡析因设计临床试验中对多剂量联合用药的评估。
Stat Med. 2000 Aug 30;19(16):2079-87. doi: 10.1002/1097-0258(20000830)19:16<2079::aid-sim535>3.0.co;2-i.

引用本文的文献

1
When should factorial designs be used for late-phase randomised controlled trials?何时应使用析因设计进行后期随机对照试验?
Clin Trials. 2024 Apr;21(2):162-170. doi: 10.1177/17407745231206261. Epub 2023 Oct 31.
2
Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities.追踪和阻断细胞BRAF-MEK癌激酶活性的相互依赖性。
PNAS Nexus. 2023 Jun 5;2(6):pgad185. doi: 10.1093/pnasnexus/pgad185. eCollection 2023 Jun.

本文引用的文献

1
Resampling-based and other multiple testing strategies with application to combination drug trials with factorial designs.基于重采样和其他多重检验策略及其在具有析因设计的联合药物试验中的应用。
Stat Methods Med Res. 2011 Oct;20(5):505-21. doi: 10.1177/0962280209105655. Epub 2010 Jul 28.
2
Resampling in multiple-dose factorial designs.多剂量析因设计中的重采样
Biom J. 2009 Dec;51(6):915-31. doi: 10.1002/bimj.200900129.
3
On Identifying Minimum Efficacious Doses in Combination Drug Trials.在联合药物试验中确定最小有效剂量
Stat Biopharm Res. 2009;1(1):39-47. doi: 10.1198/sbr.2009.0004.
4
On identifying effective and superior drug combinations via Holm's procedure based on the min tests.基于最小检验通过霍尔姆方法识别有效且更优的药物组合。
J Biopharm Stat. 2009;19(2):280-91. doi: 10.1080/10543400802622469.
5
Comparison of several testing strategies for combination drug efficacy trials based on the closure principle.基于封闭原则的联合药物疗效试验的几种测试策略比较
Stat Med. 2009 Jan 30;28(2):260-73. doi: 10.1002/sim.3462.
6
Multiple testing with minimal assumptions.在最小假设条件下进行多重检验。
Biom J. 2008 Oct;50(5):745-55. doi: 10.1002/bimj.200710456.
7
Regulatory challenges for new formulations of controlled substances in today's environment.
Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S63-7. doi: 10.1016/j.drugalcdep.2006.02.001. Epub 2006 Mar 29.
8
Closure procedures for monotone bi-factorial dose-response designs.单调双因素剂量反应设计的封闭程序。
Biometrics. 2005 Mar;61(1):269-76. doi: 10.1111/j.0006-341X.2005.030709.x.
9
Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials.在非平衡析因设计临床试验中对多剂量联合用药的评估。
Stat Med. 2000 Aug 30;19(16):2079-87. doi: 10.1002/1097-0258(20000830)19:16<2079::aid-sim535>3.0.co;2-i.
10
Multiple test procedures for dose finding.用于剂量确定的多种测试程序。
Biometrics. 1996 Mar;52(1):21-37.